ClinicalTrials.gg
RecruitingNCT07653009Updated Jun 17, 2026

Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic Arthritis

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Psoriatic Arthritis, sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Marmara University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Arthritis, Psoriatic with a site in Turkey — 6 open to participants now, 10 under way, 4 of them phase 3. Arthritis, Psoriatic · Turkey.

Planned enrollment
16th of 16
15 · median 289
Started
2026
with 1 other
No phase
6 of 31
2 open now
Registered
30th of 31
by date
Lead sponsor
2 of 31
Marmara University

Among the 31 studies in Arthritis, Psoriatic with a site in Turkey, this one is the 16th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 with no phase, and was the 30th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

6 of the 31 studies in Arthritis, Psoriatic with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Arthritis, Psoriatic with a site in Turkey, or all of them as a file.
02

Study summary

This prospective single-center interventional study aims to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on disease activity, pain, quality of life, autonomic dysfunction symptoms, and inflammatory biomarkers in patients with psoriatic arthritis (PsA). Participants diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis (CASPAR) will undergo non-invasive auricular vagus nerve stimulation using the Vagustim device. Clinical outcomes including the Disease Activity Index for Psoriatic Arthritis (DAPSA), Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain scores, sleep quality, quality of life, anxiety/depression, and inflammatory markers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) will be evaluated before and after treatment.

Read the detailed description

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease characterized by heterogeneous clinical manifestations including peripheral arthritis, spondylitis, enthesitis, and dactylitis. Although currently available pharmacological therapies such as conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs, and targeted synthetic DMARDs are effective in many patients, treatment response may vary, and long-term use may be associated with adverse effects, infection risk, high cost, and treatment resistance.

Recent neuroimmunology studies have demonstrated that the vagus nerve plays a significant role in modulation of inflammatory responses through the cholinergic anti-inflammatory pathway. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique targeting the auricular branch of the vagus nerve and has emerged as a potentially safe and reproducible therapeutic approach in inflammatory disorders.

Previous studies have shown that vagus nerve stimulation may reduce inflammatory cytokine production and improve clinical outcomes in diseases such as rheumatoid arthritis and systemic lupus erythematosus. However, evidence regarding the clinical and biological effects of taVNS in patients with psoriatic arthritis remains limited.

The aim of this prospective, single-center, single-arm interventional study is to evaluate the effects of taVNS on disease activity, pain, functional status, quality of life, autonomic dysfunction symptoms, sleep quality, anxiety/depression symptoms, and inflammatory biomarkers including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in patients with PsA diagnosed according to the Classification Criteria for Psoriatic Arthritis (CASPAR).

Eligible participants aged 18-65 years with moderate-to-severe disease activity will undergo non-invasive auricular vagus nerve stimulation using the Vagustim device. Electrodes will be placed on the tragus and cymba conchae regions of the auricle, and electrical stimulation will be applied for 20 minutes per session according to predefined stimulation parameters.

Clinical assessments including the Disease Activity Index for Psoriatic Arthritis (DAPSA), Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Visual Analog Scale (VAS) pain scores, the Short Form-12 Health Survey (SF-12), Pittsburgh Sleep Quality Index (PSQI), Composite Autonomic Symptom Score-31 (COMPASS-31), Hospital Anxiety and Depression Scale (HADS), and Fibromyalgia Rapid Screening Tool (FiRST) will be evaluated before and after treatment.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Transcutaneous Auricular Vagus Nerve Stimulation
  • Vagus Nerve Stimulation
  • Autonomic Dysfunction Disease Activity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of psoriatic arthritis according to the CASPAR criteria
  • Age between 18 and 65 years
  • Stable treatment regimen for at least 12 weeks prior to enrollment
  • Visual Analog Scale (VAS) pain score ≥4 on a 0-10 scale
  • Moderate-to-high disease activity according to the Disease Activity Index for Psoriatic Arthritis (DAPSA)
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Presence of an implanted cardiac device (e.g., pacemaker, implantable cardioverter-defibrillator) or implanted neurostimulator
  • History of epilepsy or other uncontrolled neurological disorders
  • Active severe infection or condition (e.g., sepsis)
  • Pregnancy or breastfeeding
  • Presence of deep auricular injury, previous ear surgery, or active skin lesions involving the auricle
  • Inability to comply with the treatment protocol or history of severe psychiatric disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    taVNS Group

    Participants with psoriatic arthritis will receive transcutaneous auricular vagus nerve stimulation (taVNS) using the Vagustim device. Electrical stimulation will be applied through electrodes placed on the tragus and cymba conchae regions of the auricle for 20 minutes per session over a 10-day treatment period.

    Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation (taVNS)

    Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) will be administered using the Vagustim device. Electrodes will be placed on the tragus and cymba conchae regions of the auricle, which are anatomically associated with the auricular branch of the vagus nerve. Electrical stimulation will be applied for 20 minutes per session over a 10-day treatment period while participants are in a seated position. All procedures will be performed according to standardized stimulation parameters and patient safety protocols.

06

What researchers measure

Primary outcomes

  1. Change in Disease Activity According to Disease Activity Index for Psoriatic Arthritis (DAPSA)

    Disease activity will be assessed using the Disease Activity Index for Psoriatic Arthritis (DAPSA). Higher scores indicate greater disease activity and worse clinical status.

    Time frame: Baseline, Day 10, and Month 3

Secondary outcomes

  1. Change in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    Disease activity and symptom severity will be assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Scores range from 0 to 10, with higher scores indicating greater disease activity and symptom burden.

    Time frame: Baseline, Day 10, and Month 3

  2. Change in Disease Activity According to Ankylosing Spondylitis Disease Activity Score Based on C-Reactive Protein (ASDAS-CRP)

    Disease activity will be evaluated using the Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP). Higher scores indicate greater inflammatory disease activity and worse clinical status.

    Time frame: Baseline, Day 10, and Month 3

  3. Change in Pain Severity According to Visual Analog Scale (VAS)

    Pain severity will be assessed using the Visual Analog Scale (VAS), a validated self-reported measure in which participants rate their pain intensity on a scale ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: Baseline, Day 10, and Month 3

  4. Change in Global Disease Assessment According to Visual Analog Scale Global Assessment (VAS Global)

    Participants' overall perception of disease activity will be assessed using the Visual Analog Scale Global Assessment (VAS Global), scored from 0 to 10. Higher scores indicate greater perceived disease activity and worse health status.

    Time frame: Baseline, Day 10, and Month 3

  5. Change in Disease Activity According to Physician Global Assessment (PGA)

    Overall disease activity will be evaluated using the Physician Global Assessment, scored from 0 to 10. Higher scores indicate greater disease activity and worse clinical status as assessed by the physician.

    Time frame: Baseline, Day 10, and Month 3

  6. Change in Psoriasis Severity According to Psoriasis Area and Severity Index (PASI)

    Psoriasis severity and extent of skin involvement will be assessed using the Psoriasis Area and Severity Index (PASI). Scores range from 0 to 72, with higher scores indicating more severe psoriasis and greater skin involvement.

    Time frame: Baseline, Day 10, and Month 3

  7. Change in Quality of Life According to Short Form-12 Health Survey (SF-12)

    Health-related quality of life will be assessed using the Short Form-12 Health Survey (SF-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: Baseline, Day 10, and Month 3

  8. Change in Sleep Quality According to Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality and sleep disturbances will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Scores range from 0 to 21, with higher scores indicating poorer sleep quality and greater sleep disturbance.

    Time frame: Baseline, Day 10, and Month 3

  9. Change in Autonomic Dysfunction Symptoms According to Composite Autonomic Symptom Score-31 (COMPASS-31)

    Autonomic nervous system symptoms will be assessed using the Composite Autonomic Symptom Score-31 (COMPASS-31). Scores range from 0 to 100, with higher scores indicating greater autonomic symptom burden and worse autonomic dysfunction.

    Time frame: Baseline, Day 10, and Month 3

  10. Change in Anxiety and Depression Symptoms According to Hospital Anxiety and Depression Scale (HADS)

    Symptoms of anxiety and depression will be evaluated using the Hospital Anxiety and Depression Scale (HADS). Total scores range from 0 to 42, with higher scores indicating greater psychological distress.

    Time frame: Baseline, Day 10, and Month 3

  11. Change in Fibromyalgia Symptoms According to Fibromyalgia Rapid Screening Tool (FiRST)

    Fibromyalgia-related symptoms will be screened using the Fibromyalgia Rapid Screening Tool (FiRST). Scores range from 0 to 6, with higher scores indicating a greater likelihood of fibromyalgia.

    Time frame: Baseline, Day 10, and Month 3

  12. Change in C-Reactive Protein (CRP) Level

    Inflammatory activity will be evaluated by measuring serum C-reactive protein (CRP) levels. Higher values indicate greater systemic inflammation.

    Time frame: Baseline, Day 10, and Month 3

  13. Achievement of Minimal Disease Activity (MDA)

    Minimal Disease Activity (MDA) status will be assessed as a composite outcome according to established Psoriatic Arthritis Minimal Disease Activity criteria. Participants will be classified as achieving or not achieving MDA at each assessment time point.

    Time frame: Baseline, Day 10, and Month 3

  14. Change in Functional Status According to Health Assessment Questionnaire (HAQ)

    Functional disability and daily living activities will be evaluated using the Health Assessment Questionnaire (HAQ). Scores range from 0 to 3, with higher scores indicating greater functional impairment and disability.

    Time frame: Baseline, Day 10, and Month 3

  15. Change in Erythrocyte Sedimentation Rate (ESR)

    Inflammatory activity will be evaluated by measuring erythrocyte sedimentation rate (ESR). Higher values indicate greater systemic inflammation.

    Time frame: Baseline, Day 10, and Month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Brock C, Rasmussen SE, Drewes AM, Moller HJ, Brock B, Deleuran B, Farmer AD, Pfeiffer-Jensen M. Vagal Nerve Stimulation-Modulation of the Anti-Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or Ankylosing Spondylitis. Mediators Inflamm. 2021 May 27;2021:9933532. doi: 10.1155/2021/9933532. eCollection 2021. PubMed 34135691 ↗

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared. Aggregated results will be reported in publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 17, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jun 2, 2027
CompletionEst.
Aug 2, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653009
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 2, 2026
Primary completion
Jun 2, 2027 (estimated)
Completion
Aug 2, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Zeynep M Kurt, MD
Contact
kurtzeynepmelis@gmail.com
+90 533 485 59 11
Halise Hande Gezer, MD, Associate Professor
principal investigator · Marmara University Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion